Skip to main content
HEALTHYEATS GUIDE
Disease Prevention and Management

Exdensur for Asthma: 7 Essential Facts to Know

Exdensur for asthma explained: how depemokimab works, who qualifies, the twice-yearly dosing schedule, trial results, side effects and its nasal polyp status.

By

Published

Updated

10 min read

Introduction

Exdensur (depemokimab-ulaa) is a biologic medicine for severe asthma driven by eosinophils, a type of white blood cell that fuels airway inflammation. The FDA approved it on December 16, 2025, as an add-on maintenance treatment for adults and children aged 12 and older whose severe asthma has an eosinophilic phenotype. Its standout feature is the schedule: one injection every six months.

For people who keep having asthma attacks despite high-dose inhalers, a twice-yearly treatment can be appealing. But Exdensur is not a rescue medicine; it is not for everyone with asthma, and its approval covers asthma only in the United States. This guide explains seven essential facts, drawing on the FDA-approved prescribing information, so you can have a better-informed conversation with your asthma specialist.

1. What Is Exdensur and Why Does It Matter for Asthma?

Healthcare professional explaining Exdensur side effects and fever symptoms

Exdensur is a monoclonal antibody that blocks interleukin-5 (IL-5), a signaling protein that helps eosinophils grow, survive and gather in the airways. It belongs to the same drug class as mepolizumab and reslizumab, but it was engineered to last much longer in the body.

Understanding eosinophilic asthma

In eosinophilic asthma, high numbers of eosinophils inflame and narrow the airways. People with this type often have frequent flare-ups, need repeated courses of oral steroids, and may also have nasal polyps or chronic sinus problems. A blood test showing raised eosinophils, together with symptoms and attack history, helps identify it. In the trials that led to approval, eligible patients had a blood eosinophil count of at least 150 cells per microliter at screening, or at least 300 in the previous year.

Why targeted biologic treatments are needed

Most asthma improves with inhaled corticosteroids and bronchodilators. Severe asthma is the smaller group that stays uncontrolled despite those medicines taken correctly. Repeated oral steroid courses carry real long-term risks, including bone loss, weight gain, diabetes and cataracts, so treatments that cut attacks without steroids matter.

The role of IL-5 in asthma inflammation

IL-5 acts like a recruitment signal for eosinophils. Blocking it lowers eosinophil levels in the blood and airways. In the Exdensur trials, blood eosinophils fell by about 79% compared with placebo after a year.

Treatment TypeMain PurposeExamples
Inhaled corticosteroidsReduce general airway inflammationController inhalers.
BronchodilatorsRelax airway musclesRescue inhalers
Oral corticosteroidsControl severe flare-upsShort-term steroid courses
Biologic therapiesTarget specific immune pathwaysIL-5 inhibitors

2. How Does Exdensur Work for Asthma?

Doctor consultation about Depemokimab uses for asthma management

Exdensur binds to IL-5 so it cannot attach to its receptor on eosinophils. Without that signal, fewer eosinophils mature and survive, and airway inflammation calms down over time.

Blocking the eosinophil pathway

Because the antibody has a long half-life, a single 100 mg dose keeps working for months. That is what makes the six-month dosing interval possible.

Benefits seen in clinical research

The approval was based on two 52-week trials, SWIFT-1 and SWIFT-2, which included 762 people aged 12 and older with severe eosinophilic asthma. Everyone kept their usual asthma medicines and added either Exdensur or placebo every six months. According to the prescribing information:

  • The yearly rate of clinically significant asthma attacks was 58% lower in SWIFT-1 and 48% lower in SWIFT-2 compared with placebo.
  • About 32% of people on Exdensur had at least one attack during the year, compared with 46% to 50% on placebo.
  • Attacks needing a hospital stay or emergency visit were less common with Exdensur than with placebo.

How Exdensur differs from other biologics

Other IL-5 pathway biologics are given every four or eight weeks. Exdensur's twice-yearly schedule means fewer clinic visits and may help people who struggle to keep up with frequent injections. Head-to-head trials against other biologics have not been published, so your specialist will choose based on your test results, other conditions, preferences and insurance coverage.

3. Who Is a Candidate for Exdensur?

Medical team reviewing IL-5 antagonist medicine for asthma care

Exdensur is meant for a specific group of people with asthma, not as a first step.

Patients who may benefit

A person may be considered if they:

  • Are 12 years or older
  • Have severe asthma with an eosinophilic phenotype
  • Keep having attacks despite inhaled controller medicines
  • Want to reduce their need for oral steroid courses

Importance of medical evaluation

Before starting, a specialist usually confirms the asthma diagnosis, checks inhaler technique and adherence, measures blood eosinophils and treats other factors such as allergies, reflux or smoking. The label also advises treating any existing parasitic (helminth) infection before the first dose, because eosinophils help the body fight some parasites.

Add-on maintenance therapy approach

Exdensur is added to your current inhalers. It does not replace them, and it should never be used to treat a sudden asthma attack.

4. What Is the Exdensur Dosage Schedule?

Medication organizer showing Exdensur dosage schedule information

How often is Exdensur given?

The recommended dose is 100 mg injected under the skin once every six months. If a dose is missed, it is given as soon as possible, and the six-month schedule restarts from that date.

Administration method

A healthcare provider gives the injection into the upper arm, thigh or abdomen, avoiding the two inches around the navel and any tender, bruised, red or hard skin. The pen or syringe is taken out of the refrigerator about 30 minutes beforehand so it reaches room temperature.

Staying consistent with treatment

Two appointments a year are easy to forget. Put the next date in your calendar as soon as you leave the clinic. Do not stop your inhaled or oral steroids suddenly after starting a biologic; any reduction should be gradual and supervised.

FeatureInformation
Active ingredientDepemokimab
Medication typeBiologic asthma medication
Target pathwayIL-5/eosinophil inflammation pathway
Main useSevere eosinophilic asthma
Treatment roleAdd-on maintenance therapy

The active ingredient is spelled depemokimab (full nonproprietary name depemokimab-ulaa).

5. What Are the Side Effects of Exdensur?

Patient experiencing asthma symptoms before Exdensur treatment benefits

Common possible reactions

In the trials, the most common side effects (in at least 4% of people) were upper respiratory tract infections, allergic rhinitis, flu, joint pain and sore throat. Injection-site reactions such as redness, swelling or itching occurred in about 1% of patients.

Rare but serious reactions

Allergic (hypersensitivity) reactions, including anaphylaxis, can occur after a dose. Symptoms may include hives, swelling of the face or throat, dizziness or trouble breathing. Our article on biphasic anaphylaxis explains why severe reactions need emergency care even if they seem to ease.

Do not stop your inhaled or oral steroids suddenly when you start Exdensur. If your doses can be lowered, your doctor will reduce them gradually.

Discussing risks with your doctor

Tell your specialist about any parasitic infection, pregnancy or plans to become pregnant, and all other medicines. If your asthma suddenly gets worse after starting Exdensur, seek medical help rather than waiting for the next dose.

6. Is Exdensur Used for Nasal Polyps?

Doctor discussing Exdensur for asthma treatment with patient guidance

Connection between asthma and nasal polyps

Many people with eosinophilic asthma also have chronic rhinosinusitis with nasal polyps (CRSwNP), because the same type of inflammation affects the nose and sinuses. Our guide to what are nasal polyps covers symptoms and standard care.

Current treatment decisions

In the United States, Exdensur is approved only for severe eosinophilic asthma. On the same day it approved the asthma use in December 2025, the FDA did not approve the separate application for nasal polyps at that time, raising questions about the size of the benefit shown. This decision did not affect the asthma approval. Regulators in some other countries, including the United Kingdom, have approved it for both conditions, so availability depends on where you live.

Importance of specialist guidance

If you have both asthma and nasal polyps, ask your specialist which approved treatment best covers both conditions in your country.

7. What Should Patients Know Before Starting Exdensur?

Patient using inhaler during eosinophilic asthma treatment at home

Practical steps before treatment

Bring a record of your attacks, steroid courses and emergency visits from the past year. Ask about insurance approval, since biologics usually need prior authorization. Confirm who will give the injection and when.

Lifestyle habits that support asthma management

Biologics work best alongside good daily care. Keep taking your controller inhaler, avoid smoke, reduce allergen exposure at home and keep up with flu and other recommended vaccines. Our article on dust allergy offers practical tips for one common indoor trigger.

Working with your healthcare team

Review your progress with your specialist after six to twelve months. Fewer attacks, fewer steroid courses and better daily control are signs it is working.

When to See a Doctor

Contact your asthma care team if you:

  • Use your rescue inhaler more than usual or wake at night with symptoms
  • Have hives, rash or swelling after an injection
  • Develop signs of a parasitic infection, such as unexplained diarrhea or weight loss after travel
  • Feel your asthma is not improving after several months of treatment

Emergency: Call 911 (or your local emergency number) if you have severe shortness of breath, cannot speak in full sentences, have blue or gray lips, your rescue inhaler is not helping, or you develop swelling of the face or throat after a dose.

Conclusion

Exdensur offers people with severe eosinophilic asthma a long-acting option: one 100 mg injection every six months, added to their usual inhalers. In trials it cut the yearly attack rate by roughly half and was generally well tolerated, with respiratory infections and joint pain among the most common side effects. It is not a rescue treatment; it requires specialist assessment, and in the United States it is not approved for nasal polyps. A frank discussion with your specialist is the best way to decide whether it fits your plan.

Sources

FAQ

1. When was Exdensur approved by the FDA?

The FDA approved Exdensur (depemokimab-ulaa) on December 16, 2025, for add-on maintenance treatment of severe eosinophilic asthma in people aged 12 and older.

2. How often is Exdensur given?

It is given as a 100 mg injection under the skin once every six months by a healthcare provider.

3. Can Exdensur be used during an asthma attack?

No. Exdensur is a long-term maintenance medicine and does not relieve sudden symptoms. Use your rescue inhaler and seek emergency help for a severe attack.

4. What are the most common side effects of Exdensur?

In trials, the most common were upper respiratory infections, allergic rhinitis, flu, joint pain and sore throat. Serious allergic reactions are rare but possible.

5. Is Exdensur approved for nasal polyps in the US?

Not at present. In December 2025 the FDA did not approve the separate application for chronic rhinosinusitis with nasal polyps, although some other countries, including the United Kingdom, have approved that use.

About the author

Photo of Haider Nadeem

Health Researcher and Writer

Haider Nadeem is a health researcher and the writer behind Healthy Eats Guide. He writes about health problems he faces or sees people around him face, and turns careful research into practical guides. Articles are researched and drafted with AI assistance, then fact-checked and edited by Haider using cited sources such as USDA, NIH, and peer-reviewed research.

More about Haider Nadeem and how articles are made

Related blogs

Exhausted woman coping with Mounjaro fatigue and reduced Mounjaro energy levels.
Disease Prevention and Management

Mounjaro Fatigue: 5 Essential Facts to Know

Mounjaro fatigue explained: what the FDA label says, 5 key facts about tirzepatide tiredness, common causes like low intake and dehydration, and when to seek care.

9 min read

Couple talking with a doctor about cystic fibrosis
Disease Prevention and Management

Cystic Fibrosis: 7 Essential Facts You Should Know

Cystic fibrosis explained: the CFTR gene, inheritance, symptoms, newborn screening and sweat test, CFTR modulators, life expectancy and daily care.

9 min read

Newsletter

Get practical nutrition guides in your inbox

Clear food-by-food advice and diet tips for everyday eating — no spam, unsubscribe anytime.

How often should we email you?

We’ll only email you about nutrition and diet. Unsubscribe anytime. Privacy Policy.